CHLORDECONE EXPOSURE and PROSTATE CANCER in the FRENCH REGION of MARTINIIQUE

Launched by INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, FRANCE · Jan 8, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Chlordecone Exposure and Prostate Cancer in the French Region of Martinique," aims to explore the potential link between exposure to a pesticide called chlordecone and the development of prostate cancer in men living in Martinique. Prostate cancer is a serious health issue, particularly among men of Afro-Caribbean descent, who have higher rates of this disease compared to other populations. Researchers are particularly interested in understanding how environmental factors, like chlordecone, might influence prostate cancer risk.

To participate in this study, men under 75 years old who have recently been diagnosed with prostate cancer in Martinique can enroll. Additionally, there are two groups of control participants: one group includes men who had a negative biopsy after high prostate-specific antigen (PSA) levels, and the other group consists of men with normal PSA levels. All participants will be asked to provide informed consent and will be involved in helping researchers gather important information about the relationship between chlordecone and prostate cancer. This study is crucial for understanding how environmental factors may affect health and could lead to better prevention and treatment strategies in the future.

Gender

MALE

Eligibility criteria

• • INCLUSION CRITERIA
• To take part in this research, participants must meet the following criteria:
• Patients/cases :
• • All men newly diagnosed with Prostate Cancer in Martinique during a three-year given period in all public and private services caring for patients with Prostate Cancer, identified via multidisciplinary consultation meetings.
• • Male adults under 75 years of age
• • Resident in Martinique for at least 6 months
• • Histologically confirmed (inclusion possible as soon as the result is known by the urologist)
• • Affiliated to a social security scheme or equivalent
• • Have signed a free and informed consent form
• Biopsy-negative" controls (Group 1 controls):
• • All men with a negative prostate biopsy following elevated Prostate Specific Antigen (PSA) assay (\> 2.5 ng/ml) within a 3-year period in all public and private services in Martinique identified via urologists or pathologists.
• • Male adults under 75 years of age
• • Resident in Martinique for at least 6 months
• • Frequency matched on age (+/- 5 years) to patients
• • Affiliated to a social security scheme or equivalent
• • Signed free and informed consent
• PSA-negative" controls (Group 2 controls):
• • All men with a PSA ⩽ 2.5 ng/ml within a 3-year period and less than 3 months identified via a survey institute
• • Male adults under 75 years of age
• • Resident in Martinique for at least 6 months
• • Frequency matched on age (+/- 5 years) against patients
• • Frequency matched on socio-professional category against men of the same age in Martinique (INSEE data)
• • NON INCLUSION CRITERIA
• To take part in this research, participants must not meet the following criteria:
• • Be subject to a legal protection measure (safeguard of justice, curatorship or guardianship).
• • Inability to consent because does not speak French or Creole.